All In MedTech

Device Trial Radar · NCT04702802

Study to Evaluate the Safety of the Viscoelastic Substance PRO-149, Compared to Healon® EndoCoat.

Clinical Study to Evaluate the Safety of the Viscoelastic Substance PRO-149 When Used as a Device During Phacoemulsification and Intraocular Lens Implantation in Patients With Age-related Cataract, Compared to Healon® EndoCoat.

Last checked: Nov 20, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Sep 7, 2021

Primary completion

Oct 29, 2021

Study completion Oct 29, 2021

Sponsor

Lead sponsor
Laboratorios Sophia S.A de C.V.Not on our public-company list
Sponsor type
Industry
First posted
Jan 11, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pilot, controlled, parallel group, open, randomized clinical trial to evaluate the safety of the viscoelastic substance PRO-149 (sodium hyaluronate 3%) after trans-surgical administration as a device in performing phacoemulsification and intraocular lens implantation in 36 patients with age-related cataract, compared to Healon® EndoCoat (sodium hyaluronate 3%).

Conditions

  • Age-related Cataract
  • Phacoemulsification

Interventions

  • Sodium hyaluronate 3%Device

    During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.

  • Sodium hyaluronate 3%Device

    During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Corneal Endothelial Cell CountTime frame: Days: -15 (±2) (eligibility visit), and 29 (±2) (final visit)
  2. Change in Intraocular Pressure (IOP)Time frame: Days: -15 (±2) (eligibility visit [EV]), 1 (first safety evaluation visit [V1]), 8 (±2) (second safety evaluation visit [V2]), and 29 (±2) (final visit [FV])

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SalaUno Salud, S.A.P.I. de C.V.

    Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.